ANI Pharmaceuticals has been treading water for the past six months, holding steady at $57.79.

Is there a buying opportunity in ANI Pharmaceuticals, or does it present a risk to your portfolio? See what our analysts have to say in our full research report, it’s free.

Why Is ANI Pharmaceuticals Not Exciting?

We're cautious about ANI Pharmaceuticals. Here are three reasons why there are better opportunities than ANIP and a stock we'd rather own.

1. Fewer Distribution Channels Limit its Ceiling

Larger companies benefit from economies of scale, where fixed costs like infrastructure, technology, and administration are spread over a higher volume of goods or services, reducing the cost per unit. Scale can also lead to bargaining power with suppliers, greater brand recognition, and more investment firepower. A virtuous cycle can ensue if a scaled company plays its cards right.

With just $674.1 million in revenue over the past 12 months, ANI Pharmaceuticals is a small company in an industry where scale matters. This makes it difficult to build trust with customers because healthcare is heavily regulated, complex, and resource-intensive.

2. Shrinking Adjusted Operating Margin

Adjusted operating margin is one of the best measures of profitability because it tells us how much money a company takes home after subtracting all core expenses, like marketing and R&D. It also removes various one-time costs to paint a better picture of normalized profits.

Analyzing the trend in its profitability, ANI Pharmaceuticals’s adjusted operating margin decreased by 7 percentage points over the last five years. This raises questions about the company’s expense base because its revenue growth should have given it leverage on its fixed costs, resulting in better economies of scale and profitability. Its adjusted operating margin for the trailing 12 months was 25.1%.ANI Pharmaceuticals Trailing 12-Month Operating Margin (Non-GAAP)

3. Previous Growth Initiatives Have Lost Money

Growth gives us insight into a company’s long-term potential, but how capital-efficient was that growth? A company’s ROIC explains this by showing how much operating profit it makes compared to the money it has raised (debt and equity).

ANI Pharmaceuticals’s five-year average ROIC was negative 4.6%, meaning management lost money while trying to expand the business. Its returns were among the worst in the healthcare sector.ANI Pharmaceuticals Trailing 12-Month Return On Invested Capital

Final Judgment

ANI Pharmaceuticals isn’t a terrible business, but it isn’t one of our picks. That said, the stock currently trades at 9× forward P/E (or $57.79 per share). While this valuation is optically cheap, the potential downside is big given its shaky fundamentals. We're pretty confident there are more exciting stocks to buy at the moment. We’d recommend looking at one of our top digital advertising picks.

Story Continues

Stocks We Like More Than ANI Pharmaceuticals

Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.

While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

View Comments